Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.16
+0.33 (1.85%)
At close: Jun 24, 2026, 4:00 PM EDT
18.16
0.00 (0.00%)
After-hours: Jun 24, 2026, 5:54 PM EDT
Avalo Therapeutics Employees
Avalo Therapeutics had 33 employees as of December 31, 2025. The number of employees increased by 10 or 43.48% compared to the previous year.
Employees
33
Change (1Y)
10
Growth (1Y)
43.48%
Revenue / Employee
$1,788
Profits / Employee
-$2,567,879
Market Cap
956.17M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 33 | 10 | 43.48% | 33 | 0 |
| Dec 31, 2024 | 23 | 4 | 21.05% | 23 | 0 |
| Dec 31, 2023 | 19 | -1 | -5.00% | 19 | 0 |
| Dec 31, 2022 | 20 | -24 | -54.55% | 20 | 0 |
| Dec 31, 2021 | 44 | 13 | 41.94% | 42 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Pharming Group | 407 |
| Kura Oncology | 260 |
| Geron | 258 |
| Olema Pharmaceuticals | 137 |
| Alpha Tau Medical | 121 |
| Janux Therapeutics | 108 |
| ORIC Pharmaceuticals | 104 |
AVTX News
- 1 day ago - Avalo Therapeutics Appoints Ron Philip to Board of Directors - GlobeNewsWire
- 8 days ago - Avalo Therapeutics advances AVTX-010 - TheFly
- 8 days ago - Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody - GlobeNewsWire
- 12 days ago - Avalo Therapeutics initiated with a Buy at BofA - TheFly
- 22 days ago - Avalo Therapeutics Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Avalo Therapeutics price target lowered to $34 from $40 at Wedbush - TheFly
- 5 weeks ago - Avalo Therapeutics price target raised to $45 from $39 at Mizuho - TheFly